Home > Press > Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer
Abstract:
Keystone Nano is pleased to announce that that it has received orphan drug status for the use of Ceramide to treat Liver Cancer from the FDA. This very important designation provides key benefits to the company including a period of market exclusivity upon product approval. "We are pleased to be granted orphan drug status as this helps Keystone Nano accelerate the development of Ceramide NanoLiposome (KN-001) for the patients battling Liver Cancer," remarked Jeff Davidson, Keystone's Chief Executive Officer.
Evidence collected in a very large number of carefully conducted research tests (in vitro and in vivo) demonstrate that Ceramides can kill cancer cells while leaving normal cells alone, providing treatment without undo toxicity. Ceramides have not been previously tested as cancer therapies, and Keystone Nano has developed a highly unique NanoLiposome designed to deliver Ceramide effectively to cancer cells. Keystone Nano has conducted a large number of preclinical tests on the Ceramide NanoLiposome exploring its safety and is planning clinical testing in the near future.
Liver Cancer currently kills approximately 25,000 people in the United States, and kills approximately 700,000 worldwide. There is not currently an effective therapy for this disease.
Keystone has a 90 second animation that describes its technology at: https://www.youtube.com/watch?v=2rjcx4G0Vl0 . The animation highlights a few key aspects of the technology. More detail can be found at the web site, including links to many published papers describing the science conducted to date.
####
About Keystone Nano
Based in State College, PA, Keystone Nano is working at the interface between nanotechnology and the life sciences. The company is commercializing Ceramide NanoLiposome and additional products using NanoJackets, calcium phosphate nanoparticles that may be targeted to specific cell types, for a variety of medical applications. The Company's product pipeline is protected by a patent portfolio comprised of 11 patent families that has resulted in 14 issued patents and 8 pending applications to date.
For more information, please click here
Contacts:
Copyright © Keystone Nano
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
Videos/Movies
New X-ray imaging technique to study the transient phases of quantum materials December 29th, 2022
Solvent study solves solar cell durability puzzle: Rice-led project could make perovskite cells ready for prime time September 23rd, 2022
Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022
Visualizing the invisible: New fluorescent DNA label reveals nanoscopic cancer features March 4th, 2022
Govt.-Legislation/Regulation/Funding/Policy
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Institute for Nanoscience hosts annual proposal planning meeting May 16th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Nanobiotechnology
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |